DexCom rises as Evercore lifts PT on potential diabetes device insurance coverage

Shares of medical device maker DexCom DXCM.O rise 1.93% to $67.21

Evercore ISI raises PT to $90 and upgrades rating to "outperform"

Brokerage says DXCM could benefit as U.S. health programmes move toward covering glucose monitors for more patients with Type 2 diabetes who do not use insulin

Says a clinical study testing DXCM's glucose monitor in these patients, due in 2Q26, could support Medicare coverage in late 2026, giving access to about 12 million patients; commercial insurers may follow

Brokerage sees faster customer growth from 2028 helped by the roll out of co's new 15-day glucose sensor

Expects double-digit revenue growth through 2028

DXCM shares were down over 14% in 2025